Abstract: The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides methods of treating breast cancer using antibodies that bind to GPNMB, immunoconjugates and other derivatives thereof.

Abstract: The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides methods of treating breast cancer using antibodies that bind to GPNMB, immunoconjugates and other derivatives thereof.

Abstract: Thrombospondin-binding molecules and fragments comprising one or more regions of the TSP-1-binding domains of Histidine-Rich Glycoprotein (HRGP) are provided. Also provided are homologs of TSP-1-binding domains of Histidine-Rich Glycoprotein. Therapeutic methods of use of these thrombospondin-binding molecules and fragments, as well as anti-HRGP antibodies and antibody fragments are disclosed. These methods are useful in modulating a variety of physiological and pathological processes including angiogenesis, inflammatory responses, embryogenesis and tumor proliferation. A range of assay methods for diagnosis and for detection, quantitation and identification of modulators of the TSP-l-binding activity of HRGP are also provided. In addition screening assays for compounds that specifically modulate HRGP expression are provided. These assays are useful in a range of formats from individual assays to library screening as well as high throughput assays.